New Mechanism Introduced In Healthcare Insurance Catalog: High-priced Drugs Can Be Included Through Negotiations
This article was originally published in PharmAsia News
China's Drug Catalog for National Primary Healthcare Insurance, Occupational Accident Insurance, and Birth Insurance - also known as Healthcare Insurance Catalog - has been reviewed, and revisions will be announced in late November, according to Wang Dong Jin, Chairman of the Resident Healthcare Evaluation Expert Committee
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.